Blog

CAR T-cell therapy effective for chronic lymphocytic leukemia – Healio

CAR T-cell therapy effective for chronic lymphocytic leukemia
Healio
CD19-specific chimeric antigen receptor-modified Tcell therapy induced durable molecular remissions in patients with high-risk chronic lymphocytic leukemia who had previous treatment failure with ibrutinib, according to results from a phase 1/phase 2

2017-08-15 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.